AU2021105710A4 - A novel anti-neoplastic agents for targeting colon carcinoma cells - Google Patents
A novel anti-neoplastic agents for targeting colon carcinoma cells Download PDFInfo
- Publication number
- AU2021105710A4 AU2021105710A4 AU2021105710A AU2021105710A AU2021105710A4 AU 2021105710 A4 AU2021105710 A4 AU 2021105710A4 AU 2021105710 A AU2021105710 A AU 2021105710A AU 2021105710 A AU2021105710 A AU 2021105710A AU 2021105710 A4 AU2021105710 A4 AU 2021105710A4
- Authority
- AU
- Australia
- Prior art keywords
- colon carcinoma
- carcinoma cells
- neoplastic agent
- colon
- neoplastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 68
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 59
- 229940034982 antineoplastic agent Drugs 0.000 title claims abstract description 42
- 230000008685 targeting Effects 0.000 title claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 239000000729 antidote Substances 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 5
- 230000000340 anti-metabolite Effects 0.000 claims abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 5
- 229940100197 antimetabolite Drugs 0.000 claims abstract description 5
- 239000002256 antimetabolite Substances 0.000 claims abstract description 5
- 229930013930 alkaloid Natural products 0.000 claims abstract description 4
- 229940125697 hormonal agent Drugs 0.000 claims abstract description 4
- 230000002152 alkylating effect Effects 0.000 claims abstract description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 14
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 230000002900 effect on cell Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 44
- 206010028980 Neoplasm Diseases 0.000 description 22
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 18
- 210000001072 colon Anatomy 0.000 description 17
- 210000000664 rectum Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940041181 antineoplastic drug Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229930182494 ginsenoside Natural products 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 206010038038 rectal cancer Diseases 0.000 description 4
- 201000001275 rectum cancer Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000003200 Adenoma Diseases 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 3
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 201000002313 intestinal cancer Diseases 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- -1 RhI Natural products 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 210000001731 descending colon Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003384 transverse colon Anatomy 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010067969 Cholestatic liver injury Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100038204 Large neutral amino acids transporter small subunit 1 Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091006232 SLC7A5 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical group [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000012634 Venoocclusive liver disease Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011342 chemoimmunotherapy Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000018645 hepatic veno-occlusive disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A NOVEL ANTI-NEOPLASTIC AGENTS FOR TARGETING COLON
CARCINOMA CELLS
The present invention relates to the field of biomedicine, and specifically relates to an anti
neoplastic agents targeting the colon carcinoma cells, where a substance having the ability
to bind to a receptor, wherein the receptor is uniquely expressed or overexpressed on a
surface of a colon carcinoma cell The anti-neoplastic agents is selected from the group
comprising of an alkylating and alkylating-like agent, an antimetabolites, an antitumor
antibiotics, a plant alkaloids, a Miscellaneous agents and a hormonal agents. The anti
neoplastic agents can specifically bind to colon carcinoma cells and has a nonspecific effect
on cells, and has an obvious effect, providing a reliable scientific basic for treatment. The
anti-neoplastic agent and a pharmaceutically active ingredient, or comprises the anti
neoplastic agent and the delivery vehicle described. Further, the antidote is any
pharmacological therapeutically acceptable dosage form, preferably in the form of injection.
Also, the treatment of colon carcinoma cells in any pharmaceutically acceptable dosage.
- 12 -
Description
[0001] The present disclosure relates to a composition for treatment of Colon carcinoma cells and in particular to novel Anti-neoplastic agent for targeting Coon carcinoma cells.
[0002] Cancer that starts in the colon is called colon cancer, and rectal cancer is called rectal cancer. Cancer that affects any of these organs may be called colorectal cancer. Although this is not the case in all cases, most colorectal cancers usually develop from adenoma (precancerous) polyps over time. Polyps (growth) change after a series of mutations (abnormalities) appear in the DNA of their cells. Some risk factors for colorectal cancer include colon or rectal cancer family history, diet, alcohol consumption, smoking, and inflammatory bowel disease.
[0003] Most of the colon remains inside the abdominal cavity and is called the abdominal cavity. Parts of the colon can move freely in the abdominal cavity as undigested food passes through it. Because the head in the rectum faces the large intestine, it attaches to tissues behind the abdomen called the retroperitoneal region. The end of the colon, the part that is in the retroperitoneal space, is the rectum. Unlike the rest of the colon, the rectum is held back by the tissue that surrounds it. Because of its location, treatment for rectal cancer often differs from treatment for the rest of the colon.
[0004] When colorectal cancer is diagnosed, additional tests are performed to determine the extent of the disease. This process is called staging. Staging determines how advanced colorectal cancer has become. The staging for colorectal cancer ranges from stage I, the least advanced cancer, to stage IV, the most advanced cancer.
[0005] Stage I colorectal cancers involve only the innermost layers of the colon or rectum. The likelihood of cure (excellent prognosis) for stage I colorectal cancer is over %. Stage II cancers exhibit greater growth and extension of the tumor through the wall of the colon or rectum into adjacent structures. Stage III colorectal cancers manifest the spread of cancer to local lymph nodes.
[00061 Stage IV (metastatic) colorectal cancers have spread or metastasized, to distant organs or lymph nodes far from the original tumor. With each subsequent stage of colon cancer, the risk for recurrent cancer and death due to the spread of cancer (metastasis) rises. As noted, earlier cancers have lower risks of recurrence and death. By the time an individual has stage IV colorectal cancer, the prognosis is poor. However, even in stage IV colorectal cancer (depending on where cancer has spread) the opportunity for a cure exists.
[00071 The colon is an approximately 5- to 6-foot long tube that connects the small intestine to the rectum. The colon-which along with the rectum is called the large intestine-moves and processes digesting food across your body and down towards the rectum, where it exits the body as stool.
[00081 There are several parts of the colon, including. Ascending colon in which the section is where undigested food begins its journey through the colon. Undigested food moves upwards through this section, where fluid is reabsorbed more efficiently. Second, the Transverse colon, which is Moving across the body, takes the food from one side of the body to the other (right to left). Third, is the descending colon which is once the food has travelled across the top through the transverse colon, it makes its way downward through the descending colon typically on the left side. Fourth is Sigmoid colon in which the final section of the colon, this portion is shaped like an "S" and it is the last stop before the rectum.
[0009] All cells in the body usually grow, divide, and then die to keep the body healthy and functioning normally. Sometimes this process gets out of control. Even if the cells should die, they will continue to grow and divide. When cells in the lining of the colon and rectum multiply uncontrollably, they may eventually develop into colorectal cancer.
Fortunately, most colorectal cancers start with small precancerous (adenomatous or serrated) polyps. These polyps usually grow slowly and do not cause symptoms until they become larger or cancerous. This provides an opportunity for the detection and removal of precancerous polyps before the development of cancer.
[0010] L-type amino acid transporter 1 (LAT 1) is a drug transmembrane transporter discovered in recent years. It is specifically and highly expressed on the surface of cancer cells (including kidney cancer, prostate cancer, bladder cancer, colorectal cancer, and lung cancer). Cancer, breast cancer, pancreatic cancer, lung cancer, etc.).
[0011] The function of LAT Iis mainly to transport essential amino acids required for protein synthesis to cancer cells, provide adequate "nutrient supply" for the excessive division and proliferation of cancer cells, and play an important role in the rapid proliferation of cancer cells. Therefore, if a drug can inhibit the expression of LATI, the drug can inhibit the growth of cancer cells to a certain extent, and the drug has the prospect of being an anti cancer drug.
[0012] In the process of screening drugs for the treatment of cervical cancer, saponins once became the object of attention due to their abundant plant sources, easy availability, good curative effect, and few adverse reactions. Ginseng root is the dried root of Panax ginseng C.A. Araliaceae Panax notoginseng, the main component of ginseng is ginsenoside, ginsenoside monomer compound has anti-tumor, anti-fatigue and anti-aging effects.
[0013] The content of ginsenoside Rbl and Rgl in natural plants is higher, while the content of Rg3, Rh2 and compound K is lower. A number of pharmacological studies have shown that rare ginsenosides (such as RhI, Rh2, Rg3, Rb3, etc.) have more precious pharmacological effects, and show unique curative effects in the treatment of certain intractable diseases such as tumors, thus becoming a research hotspot. Research. The main task of those skilled in the art is to process ginseng, increase the content of ginseng rare ginsenosides, screen the compatibility of drug formulations, and form effective anticancer prescriptions.
[00141 Colorectal cancer is one of the common malignant tumors in India. In recent years, the incidence of colorectal cancer in India has continued to increase. At present, the evolutionary history of normal intestinal mucosa-adenoma-carcinoma is called the generation and evolution process of intestinal cancer. APC, K-Ras, TP53, C-MYC and other genes are involved in it. The mechanism of the occurrence and development of intestinal cancer, but the specific mechanism of the occurrence and development of intestinal cancer needs to be further studied.
[0015] It is an object of the present disclosure, which provides a novel anti-neoplastic agents targeting colon carcinoma cells
[0016] The present concept of the present invention provides a method for targeting colon carcinoma cells using novel anti-neoplastic agents.
[0017] In an aspect, the present invention further discloses that A novel anti-neoplastic agent for targeting colon carcinoma cells, wherein the said method comprises of a substance having the ability to bind to a receptor, wherein the receptor is uniquely expressed or overexpressed on a surface of a colon carcinoma cell; and an anti-neoplastic agent that is selectively toxic to colon carcinoma cells, wherein the anti-neoplastic agent is coupled to the substance.
[0018] In an aspect, The novel anti-neoplastic agent for targeting colon carcinoma cells wherein the anti-neoplastic agent is selected from the group consisting of an Alkylating and alkylating-like agent, an antimetabolites, an antitumor antibiotics, a plant alkaloids, a Miscellaneous agents, a hormonal agents.
[0019] In another aspect, novel anti-neoplastic agent for targeting colon carcinoma cells wherein the anti-neoplastic agent has target binding to colon carcinoma cells and specifically binds to carcinoma cells
[00201 In another aspect, novel anti-neoplastic agent for targeting colon carcinoma cells the colon Carcinoma cells are colon cancer cells. The novel anti-neoplastic agent for targeting colon carcinoma cells according to the preparation of a carcinoma diagnostic kit comprising said anti-neoplastic agent or anti-neoplastic conjugate the preparation of an antidote for the treatment of colon carcinoma cells.
[0021] The preparation of an antidote for the treating of colon carcinoma cells, characterized in that the antidote comprises the anti-neoplastic agent and a pharmaceutically active ingredient, or comprises the anti-neoplastic agent and the delivery vehicle described in the preparation of an antidote for treating colon carcinoma cells, characterized in that the antidote is any pharmacological therapeutically acceptable dosage form, preferably in the form of injection an antidote for the treatment of colon carcinoma cells in any pharmaceutically acceptable dosage.
[0022] In an embodiment of the present disclosure, It is inferred that the foregoing description is only illustrative of the present invention, and it is not intended that invention be limited or restrictive thereto. Many other specific embodiments of the present invention will be apparent to one skilled in the art from the foregoing disclosure. All substitutions, alterations and modifications of the present invention which comes within the scope of the following claims are to which the present invention is readily susceptible without departing from the spirit of the invention. The scope of the invention should therefore be determined not with reference to appended claims along with the full scope of equivalents to which such claims are entitled.
[0023] Exemplary embodiments will now be described more fully hereinafter with reference to the accompanying drawings, in which exemplary embodiments are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. These embodiments are provided so that this disclosure will be thorough and complete and will fully convey the scope of the invention to those of ordinary skill in the art. Moreover, all statements herein reciting embodiments of the invention, as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents as well as equivalents developed in the future (i.e., any elements developed that perform the same function, regardless of structure).
[0024] The antineoplastic agents are not easily classified. Historically, they are categorized as (1) alkylating agents, (2) antimetabolites, (3) natural products, (4) hormones and antagonists, and (5) miscellaneous. In recent years, however, the miscellaneous group has come to include some of the most important agents. Anticancer agents can also be classified by indication (lymphoma, leukemia, melanoma, solid tumor), mechanism of action (such as alkylating agents, antibiotics, biological response modifiers, antiandrogens, topoisomerase inhibitors or protein kinase inhibitors), chemical structure (folic acid analog, platinum coordination complex, purine or pyrimidine analog, monoclonal antibody) or as cytotoxic or nonspecific vs noncytotoxic or targeted.
[0025] Certain subtoxic doses of anticancer drugs can have an immunomodulatory effect, thereby changing the expression of specific molecules on the surface of tumor cells. We concluded that a possible increase in tumor cell surface markers, such as those that are important for ensuring effector-target contact and triggering cell death pathways, may improve tumor cell lysis mediated by antigen (Ag) -specific T cells.
[0026] Here, in an in vitro human colon cancer cell model, we investigated whether the anticancer drugs 5-fluorouracil (5-FU), CPT-11, or cisplatin (CDDP) can increase the expression of specific tumor cell surface markers. This can then enhance the productive lytic interaction between CD8 + CTL and silver-bearing tumor cells. According to our earlier studies, IFN-y treatment has been used as a control for CTL-mediated sensitization of lysis. Pretreatment of SW480 primary colon cancer cell line with IFN-y, 5-FU, CPT-11, or CDDP can enhance the expression of ICAM-1 and Fas, leading to Ag-specific CTL-mediated lysis, including Fas-dependent.
[00271 In contrast, pretreating metastatic SW620 isolates from the same patient with IFN-y, CPT-11, or CDDP (instead of 5-FU) can enhance ICAM-1 expression, thereby inducing Ag through Fas-specific CTL-mediated lysis. only an independent mechanism. A flow cytometric detection method was then developed to measure the effect of drug treatment on caspase signaling and apoptosis caused by the interaction between tumor targets and CTL. We found that the enhanced cleavage induced by drug treatment of targets SW480 or SW620 was accompanied by an increase in caspase-3-like protease activity. Peptide based caspase inhibitors abolish CTL-mediated apoptosis, suggesting that "chemical regulation" involves regulation of the caspase pathway.
[0028] The results show for the first time that components of the caspase pathway, such as proteases like caspase-3, play an important role in sensitizing human colon cancer cells to Ag-specific CTLs using anticancer agents. Consequently, some anticancer drugs may exhibit unique immunomodulatory properties and contribute to death from human colon cancer through the use of the lytic capacity of Ag-specific CTLs, which may influence chemoimmunotherapy strategies.
[0029] Almost all anti-tumor drugs have a certain degree of hepatotoxicity, and the damage is usually due to direct and inherent toxicity. The typical manifestation is that during treatment, severe, sexual or even fatal such as sinusoidal obstruction syndrome or toxicity despite the usual dose limitation. Myelosuppressive antitumor drugs usually have stenotic toxicity.
[0030] For this reason, many anti-tumor drugs have gained a reputation for hepatotoxicity based on marketing studies, but they are fairly well tolerated and only lead to hepatic administration (especially when used for clearing blood before hematopoietic cell transplantation). Antineoplastic drugs that can cause significant direct hepatotoxicity include busulfan, cyclophosphamide, and Dacarbaplatin L-asparaginase. At lower doses, these drugs are well tolerated.
[00311 Some antineoplastic agents can also cause idiosyncratic liver injury due to immunologic or metabolic idiosyncrasy. Thus, typical drug induced cholestatic liver injury can occur in rare instances after therapy with cyclophosphamide, azathioprine, mercaptopurine, melphalan and temozolomide. Acute hepatocellular injury can occur with flutamide, bicalutamide and thalidomide. Steatohepatitis can occur with L-asparaginase, methotrexate and tamoxifen (although this pattern may be due to direct toxicity rather than idiosyncratic injury). Selected anticancer agents have also been linked to immunoallergic hepatitis or to autoimmune hepatitis-like injury
[0032] . A distinctive autoimmune pattern is found in rare instances after monoclonal antibody therapies or with the protein kinase inhibitors. The pathogenesis of these immune reactions is not always well understood. Finally, some antineoplastic agents can cause reactivation of hepatitis B, exacerbations of chronic hepatitis C, or lead to decompensation of a preexisting cirrhosis.
[00331 The novel antitumor agent targeting colon cancer cells, wherein a substance having the ability to bind to a receptor, wherein the receptor is uniquely expressed or overexpressed on the surface of colon cancer cells; and for colon cancer An antitumor agent with selective toxicity for cells, wherein the antitumor agent is coupled to the substance. New antitumor agent to target colon carcinoma cells, wherein the antitumor agent is selected from the group consisting of alkylating agent, alkylation and the like, antimetabolites, antitumor antibiotics, plant alkaloids, various agents, hormonal agents.
[0034] A new antitumor agent for a colon carcinoma cell targeting the antitumor agent has a binding to target colon carcinoma cells, and specifically binds to carcinoma cells. The colon, which is shaped like a tube, is made up of several layers, starting with the innermost layer, the mucosa (which is made up of epithelium), and then the lamina propria and muscularis mucosa.
[0035] This is surrounded by the submucosa, which is surrounded by two layers of muscle (or muscularis), and finally, the serosa layer, which is the outside layer of the tube.
The outside of the colon is covered with a layer of fat, also called adipose tissue, which contains lymph nodes and blood vessels that feed the colon tissue and the colon Carcinoma cells are colon cancer cells.
[00361 The preparation of a carcinoma diagnostic kit containing said antitumor agent or antitumor conjugate, developed several screening tests to help physicians detect colorectal cancer before symptoms appear, when it may be more treatable.
[00371 Some tests that detect adenomas and polyps, can prevent cancer, because these tests can detect and remove growths that otherwise might become cancerous. That is, screening for colorectal cancer can be a form of cancer prevention, in addition to early detection. An antidote for treating colon cancer cells is prepared.
[0038] The treatments are most likely to help you depends on your particular situation, including the location of your cancer, its stage and your other health concerns. Treatment for colon carcinoma cells usually involves surgery to remove the cancer. Other treatments, such as radiation therapy and chemotherapy, might also be recommended.
[00391 Further, the antidote comprises the anti-neoplastic agent and a pharmaceutically active ingredient, or consists of the anti-neoplastic agent and the delivery vehicle described. The antidote is any pharmacologically therapeutically acceptable dosage form, preferably in the form of injections. Preparation of an antidote for the treatment of colon carcinoma cells in any pharmaceutically acceptable dosage.
[0040] While the foregoing describes various embodiments of the invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof. The scope of the invention is determined by the claims that follow. The invention is not limited to the described embodiments, versions or examples, which are included to enable a person having ordinary skill in the art to make and use the invention when combined with information and knowledge available to the person having ordinary skill in the art.
[00411 Thus, the scope of the present disclosure is defined by the appended claims and includes both combinations and sub-combinations of the various features described hereinabove as well as variations and modifications thereof, which would occur to persons skilled in the art upon reading the foregoing description.
Claims (6)
1. A novel anti-neoplastic agent for targeting colon carcinoma cells, wherein said anti-neoplastic agent comprises of: a substance having the ability to bind to a receptor, wherein the receptor is uniquely expressed or overexpressed on a surface of a colon carcinoma cell; and an anti-neoplastic agent that is selectively toxic to colon carcinoma cells, wherein the anti-neoplastic agent is coupled to the substance.
2. The novel anti-neoplastic agent for targeting colon carcinoma cells as claimed in claim 1, wherein an anti-neoplastic agent is selected from the group consisting of an Alkylating and alkylating-like agent, an antimetabolites, an antitumor antibiotics, a plant alkaloids, a Miscellaneous agents and a hormonal agents.
3. The novel anti-neoplastic agent for targeting colon carcinoma cells as claimed in claim 1, wherein the anti-neoplastic agent has target binding to colon carcinoma cells and specifically binds to carcinoma cells.
4 The novel anti-neoplastic agent for targeting colon carcinoma cells as claimed in claim 3, wherein the colon Carcinoma cells are colon cancer cells.
5. The novel anti-neoplastic agent for targeting colon carcinoma cells as claimed in claim 2, wherein the preparation of a carcinoma diagnostic kit comprising said anti neoplastic agent or anti-neoplastic conjugate.
6 The novel anti-neoplastic agent for targeting colon carcinoma cells as claimed in claim 1, wherein the preparation of an antidote for the treatment of colon carcinoma cells.
1 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021105710A AU2021105710A4 (en) | 2021-08-17 | 2021-08-17 | A novel anti-neoplastic agents for targeting colon carcinoma cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021105710A AU2021105710A4 (en) | 2021-08-17 | 2021-08-17 | A novel anti-neoplastic agents for targeting colon carcinoma cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021105710A4 true AU2021105710A4 (en) | 2021-11-25 |
Family
ID=78610531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021105710A Ceased AU2021105710A4 (en) | 2021-08-17 | 2021-08-17 | A novel anti-neoplastic agents for targeting colon carcinoma cells |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2021105710A4 (en) |
-
2021
- 2021-08-17 AU AU2021105710A patent/AU2021105710A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201615196A (en) | The new cancer therapy indication of the cellcept | |
| Xu et al. | Synergistic effect and molecular mechanisms of traditional Chinese medicine on regulating tumor microenvironment and cancer cells | |
| Chen et al. | Biological effects and mechanisms of matrine and other constituents of Sophora flavescens in colorectal cancer | |
| Ardalan et al. | A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma | |
| O'Neil et al. | A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer | |
| Whang-Peng et al. | Clinical development and future direction for the treatment of hepatocellular carcinoma | |
| JP2016516781A (en) | Cancer treatment | |
| Ranasinghe et al. | A synopsis of modern-day colorectal cancer: Where we stand | |
| Elkady et al. | miRNAs driving diagnosis, progression, and drug resistance in multiple myeloma | |
| Sun et al. | Relevance function of microRNA-708 in the pathogenesis of cancer | |
| Teng et al. | HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila | |
| Qi et al. | Huaier granule combined with tegafur gimeracil oteracil potassium promotes stage IIb gastric cancer prognosis and induces gastric cancer cell apoptosis by regulating livin | |
| Zhang et al. | Evodiamine inhibits ESCC by inducing M-phase cell-cycle arrest via CUL4A/p53/p21 axis and activating noxa-dependent intrinsic and DR4-dependent extrinsic apoptosis | |
| Sadrkhanloo et al. | STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions | |
| AU2021105710A4 (en) | A novel anti-neoplastic agents for targeting colon carcinoma cells | |
| Bonavida et al. | Breaking tolerance to pancreatic cancer unresponsiveness to chemotherapy | |
| WO2019092455A1 (en) | Dietary product | |
| Johnson et al. | Ganoderic acid DM: an alternative agent for the treatment of advanced prostate cancer | |
| CN110201017A (en) | Arasaponin combines application of the tanshinone IIA in preparation prevention colorectal cancer drug | |
| Maji et al. | Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics | |
| Treszl et al. | Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162 | |
| CN113350507B (en) | Application of Cep55 as target in preparation of medicines for diagnosing, preventing or treating colitis | |
| Martinez-Becerra et al. | Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy | |
| CN109481687B (en) | Combination of a CDK4/6 inhibitor in combination with a HER2 inhibitor for the treatment of gastric cancer | |
| Midgley et al. | Colorectal cancer: a multidisciplinary approach |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |